2024年10月31日,临床研究合同研究组织(CRO)艾昆纬(IQV)股价在盘前交易中大幅下跌近9%,随后全天震荡下行,一度下跌6.54%,引起市场广泛关注。
高盛街分析人士认为,这一暴跌行情或系艾昆纬当日下调2024年度业绩预期所致。艾昆纬称,由于一个客户面临物流挑战导致两项大型临床试验推迟,公司预计这两项试验将延迟至2025年下半年才能重启。
在下调预期的公告中,艾昆纬表示其2024年收入预期由之前的154.3亿至155.3亿美元,下调为153.5亿至154亿美元;调整后每股收益预期上限从11.30美元下调至11.20美元,下限维持11.10美元不变。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.